Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03374254
Title Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
City of Hope National Medical Center ( Site 0102) Duarte California 91010 United States Details
Anschutz Medical Campus, Anschutz Cancer Pavilion ( Site 0106) Aurora Colorado 80045 United States Details
Yale Cancer Center ( Site 0108) New Haven Connecticut 06520 United States Details
Moffitt Cancer Center ( Site 0111) Tampa Florida 33612 United States Details
University of Chicago ( Site 0105) Chicago Illinois 60637 United States Details
Rutgers Cancer Institute of New Jersey ( Site 0107) New Brunswick New Jersey 08903-2681 United States Details
UPMC Cancer Center/Hillman Cancer Center ( Site 0113) Pittsburgh Pennsylvania 15232 United States Details
Baylor Scott and White ( Site 0110) Temple Texas 76508 United States Details
Seattle Cancer Care Alliance ( Site 0104) Seattle Washington 98109 United States Details
Northwest Medical Specialties, PLLC ( Site 0101) Tacoma Washington 98405 United States Details
Cross Cancer Institute ( Site 0123) Edmonton Alberta T6G 1Z2 Canada Details
Princess Margaret Cancer Centre ( Site 0122) Toronto Ontario M5G 2M9 Canada Details
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0124) Montreal Quebec H2X 3E4 Canada Details
Jewish General Hospital ( Site 0121) Montreal Quebec H3T 1E2 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field